Breast Implant Illness Diagnosis
Why Standard Testing Misses BII — and What Does Work
The most consistent experience of women with breast implant illness is this: test after test returns normal. Primary care. Rheumatology. Endocrinology. Neurology. Immunology. Each specialist runs their panel, finds no definitive abnormality, and offers either a new diagnosis for one subset of BII symptoms or the implicit message that nothing is physically wrong.
This experience is not a failure of the patient to describe her symptoms correctly. It is a failure of the testing framework to detect what BII actually produces.
Why Standard Tests Return Normal
Standard medical testing is built to detect acute, defined disease states. A CBC detects anemia or acute infection. An ANA panel detects established autoimmune markers. A TSH detects gross thyroid dysfunction. These tests find what they were designed to find.
Breast implant illness produces something different: chronic low-grade immune activation driven by bacterial biofilm in the implant capsule. This activation is:
Sustained but subclinical — it does not produce the acute spikes that standard tests detect
Distributed across systems — no single organ is diseased enough to trigger a clear abnormality
Driven by biofilm — standard bacterial cultures cannot detect biofilm-forming species, which grow in protected colonies that do not release planktonic bacteria into test media
This is why 29% of capsules in Dr. Whitfield's research contained bacterial contamination that would have been missed entirely by standard culture-based testing.
PCR Testing vs. Standard Culture
The distinction between PCR (polymerase chain reaction) testing and standard bacterial culture is critical for BII patients to understand.
Standard Bacterial Culture
A tissue sample is placed in growth media and observed for visible bacterial growth over days. This method detects bacteria that grow readily in standard conditions. It misses biofilm-forming bacteria. A culture result of “no growth” does not mean the capsule is sterile.
PCR Molecular Pathology
A tissue sample is processed to extract all DNA present. PCR amplifies bacterial DNA sequences, allowing identification of any bacterial species present — including biofilm-forming species that culture cannot detect. PCR identifies what is present, not just whether visible growth occurs.
If a previous surgeon performed culture testing on your capsule and reported no infection, that result does not rule out bacterial contamination. PCR testing on the capsule at the time of explant is the definitive assessment.
What a BII Evaluation Includes
A thorough BII evaluation by an experienced surgeon addresses three components:
1. Symptom History
A complete timeline of symptom onset relative to implant placement, progression of symptoms, previous diagnoses received, treatments attempted, and symptom patterns. The symptom profile — particularly multi-system involvement — is often the most diagnostic element of the evaluation before any testing is ordered.
2. Clinical Assessment
Physical examination including evaluation of the breast tissue, capsule characteristics, and implant integrity. Capsular contracture, implant displacement, and other physical findings provide clinical context that imaging alone cannot.
3. Laboratory Evaluation
While no single lab panel diagnoses BII, a targeted evaluation may include:
- ●Inflammatory markers: CRP, ESR, ferritin
- ●Autoimmune panel: ANA, anti-dsDNA, rheumatoid factor
- ●Thyroid panel: TSH, free T3, free T4, anti-TPO, anti-thyroglobulin
- ●Immune function: immunoglobulins, complement levels
- ●Complete metabolic panel, CBC
- ●Hormone panel as appropriate
Abnormal results in any of these categories support the clinical picture but are not required for BII diagnosis. Normal results do not exclude it.
Does BII Have an Official Diagnosis?
Breast implant illness does not currently have an official ICD diagnostic code in the United States. This is a significant gap that affects insurance coverage, clinical recognition, and research funding.
This does not mean BII is not a recognized clinical entity. The FDA acknowledges BII as a real condition associated with breast implants. Published research — including Dr. Whitfield's PCR capsule analysis — provides mechanistic evidence for its biological basis.
The absence of an ICD code means that BII is currently diagnosed clinically: by a surgeon with expertise in BII, based on symptom pattern, implant history, physical examination, and supporting laboratory data.
Finding a Qualified BII Evaluator
Not all plastic surgeons have equivalent experience with BII diagnosis and explant surgery. Key factors in selecting a surgeon for BII evaluation:
Volume
Surgeons who perform large numbers of explant procedures develop clinical pattern recognition that low-volume surgeons cannot. Dr. Robert Whitfield has performed over 2,000 explant procedures.
Research Engagement
Surgeons who are active in BII research stay current with the evolving understanding of BII mechanisms. Dr. Whitfield's PCR capsule research is the largest study of its kind in the medical literature.
Capsule Management Approach
Total capsulectomy — removal of the implant and complete capsule as a single intact specimen — is the standard associated with the best outcomes in BII patients.
FDA Engagement
Surgeons who have participated in FDA panel discussions on breast implant safety have direct knowledge of the regulatory and research landscape. Dr. Whitfield testified before the FDA General and Plastic Surgery Devices Panel.
Frequently Asked Questions
Schedule a BII Evaluation
Dr. Robert Whitfield, MD offers comprehensive BII evaluations in Austin, Texas and via virtual consultation for out-of-state patients.
Book a Discovery Call with Dr. Whitfield→